A Phase 3 interventional study of Dapagliflozin and Placebo for dapagliflozin in Type 1 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 131 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 — 2 open to participants now, 5 under way, 2 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 1.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 2nd registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:
St Vincent's Hospital Melbourne · Sites in Australia
Ages 24–85
Dasman Diabetes Institute · Sites in Kuwait, Qatar, Saudi Arabia
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 833 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 43 across the 23 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
18 studies in Diabetes Mellitus, Type 1 by AstraZeneca: none open now, none under way, none of them phase 3. Of 18 finished, 9 (50%) have results posted.
Among the 18 studies in Diabetes Mellitus, Type 1 by AstraZeneca, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 3, and was the 14th registered.
AstraZeneca’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 18 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Taking any antidiabetic medication (other than insulin), within 1 month prior to screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Placebo tablet orally, once daily for 52 weeks
Drug: Placebo for dapagliflozin
Tablets
Tablets
Adjusted Mean Change in HbA1c From Baseline at Week 24
Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model\[RMM\]).
Time frame: From Baseline to Week 24
Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24
Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model\[RMM\])
Time frame: From Baseline to Week 24
Adjusted Mean Percent Change in Body Weight From Baseline at Week 24
Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model\[RMM\])
Time frame: From Baseline to Week 24
Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24
Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model\[RMM\])
Time frame: From Baseline to Week 24
Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24
Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
Time frame: From Baseline to Week 24
Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24
Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose \> 70 and \<= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
Time frame: From Baseline to Week 24
Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events
Subjects with HbA1c reduction from baseline to week 24 (LOCF) \>= 0.5% and without severe hypoglycemia events
Time frame: From Baseline to Week 24
The first subject was enrolled on 11 November 2014. The last subject completed the 24-week short-term treatment period 04 January 2017 and the last subject completed the study 25 August 2017. This study was conducted at 138 sites in 17 countries.
| Milestone | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Started | 277 | 296 | 260 |
| Completed 24 week period | 252 | 273 | 232 |
| Completed | 235 | 255 | 218 |
| Not completed | 42 | 41 | 42 |
| Withdrew: Subject no longer meets study criteria | 0 | 2 | 0 |
| Withdrew: Pregnancy | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 2 |
| Withdrew: Adverse event | 11 | 14 | 9 |
| Withdrew: Withdrawal by subject | 4 | 5 | 10 |
| Withdrew: Subject request to discontinue treatment | 10 | 8 | 6 |
| Withdrew: Poor/non-compliance | 2 | 1 | 2 |
| Withdrew: Other reasons | 7 | 3 | 3 |
| Withdrew: Not entering long-term period | 2 | 3 | 5 |
Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model\[RMM\]).
| Percentage of hemoglobin | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Change in HbA1c From Baseline at Week 24 | -0.45 ± 0.0537 | -0.47 ± 0.0538 | -0.03 ± 0.0540 |
Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model\[RMM\])
| IU | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24 | -7.74 ± 1.4881 | -12.16 ± 1.4326 | 1.16 ± 1.6593 |
Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model\[RMM\])
| Kg | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Percent Change in Body Weight From Baseline at Week 24 | -3.00 ± 0.2330 | -3.67 ± 0.2299 | 0.05 ± 0.2407 |
Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model\[RMM\])
| mg/dL | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24 | -10.28 ± 1.8862 | -12.97 ± 1.9231 | 5.06 ± 1.9320 |
Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
| mg/dL | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24 | -14.92 ± 1.9915 | -16.55 ± 2.0419 | 2.38 ± 2.0477 |
Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose \> 70 and \<= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
| Percentage | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24 | 6.98 ± 0.8824 | 8.52 ± 0.9000 | -2.13 ± 0.9032 |
Subjects with HbA1c reduction from baseline to week 24 (LOCF) \>= 0.5% and without severe hypoglycemia events
| Participants | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Responders | 127 | 129 | 65 |
Collected over Onset on or after the first date of double-blind treatment and on or prior to the last day of treatment 24-week short-term period, 28-week extension period and the 30-day folllow-up period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 5 mg + Insulin | 0/277 (0%) | 37/277 (13.4%) | 123/277 (44.4%) |
| Dapagliflozin 10 mg + Insulin | 0/296 (0%) | 40/296 (13.5%) | 118/296 (39.9%) |
| Placebo + Insulin | 1/260 (0.4%) | 30/260 (11.5%) | 99/260 (38.1%) |
| Event | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 10/277 | 7/296 | 3/260 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/277 | 4/296 | 3/260 |
| KetoacidosisMetabolism and nutrition disorders | 2/277 | 4/296 | 0/260 |
| Ankle fractureInjury, poisoning and procedural complications | 0/277 | 1/296 | 2/260 |
| Vitreous haemorrhageEye disorders | 2/277 | 0/296 | 0/260 |
| KetosisMetabolism and nutrition disorders | 2/277 | 2/296 | 0/260 |
| Chest painGeneral disorders | 1/277 | 2/296 | 1/260 |
| Angina pectorisCardiac disorders | 1/277 | 0/296 | 1/260 |
| Hyperparathyroidism primaryEndocrine disorders | 0/277 | 0/296 | 1/260 |
| OphthalmoplegiaEye disorders | 0/277 | 0/296 | 1/260 |
| Event | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 51/277 | 46/296 | 48/260 |
| Urinary tract infectionInfections and infestations | 27/277 | 10/296 | 19/260 |
| Upper respiratory tract infectionInfections and infestations | 19/277 | 28/296 | 15/260 |
| DiarrhoeaGastrointestinal disorders | 11/277 | 21/296 | 9/260 |
| HeadacheNervous system disorders | 14/277 | 20/296 | 13/260 |
| InfluenzaInfections and infestations | 15/277 | 15/296 | 17/260 |
| GastroenteritisInfections and infestations | 15/277 | 10/296 | 8/260 |
| NauseaGastrointestinal disorders | 14/277 | 15/296 | 7/260 |
Safety Analysis Set: It consists of all subjects who received at least one dose of double-blind study medication during the short-term double-blind treatment period.
| Age, Continuous(Years) | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin | Total |
|---|---|---|---|---|
| Mean | 42.1 ± 13.94 | 43.4 ± 13.89 | 42.7 ± 13.57 | 42.7 ± 13.80 |
| Age, Customized(Participants) | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin | Total |
|---|---|---|---|---|
| < 65 years | 262 | 279 | 246 | 787 |
| Between 65 and 75 years | 15 | 16 | 14 | 45 |
| >= 75 years | 0 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Dapagliflozin 5 mg + Insulin | Dapagliflozin 10 mg + Insulin | Placebo + Insulin | Total |
|---|---|---|---|---|
| Female | 158 | 144 | 128 | 430 |
| Male | 119 | 152 | 132 | 403 |
Showing the first 100 of 131 sites across 17 countries. Choose a country and city above to see the rest.
Ran from Nov 2014 to primary completion in Jan 2017, 25 months.
Results were first posted in Mar 2018, 1 year 2 months after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 25 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin